See the DrugPatentWatch profile for Calquence
What does “Calquence loss of exclusivity” usually mean?
“Loss of exclusivity” for a drug like Calquence (acalabrutinib) typically refers to the point when generic manufacturers can file for approval (and, in many cases, when they can launch) because patent and regulatory exclusivities no longer block competition. That timing can be driven by different legal protections, including patents covering the drug’s active ingredient, specific formulations, or manufacturing processes, plus regulatory exclusivities tied to approvals and indications.
When could generic entry happen for Calquence?
The exact “loss of exclusivity” date depends on which protection expires first (patents vs. regulatory exclusivity vs. exclusivity tied to a specific indication). DrugPatentWatch.com tracks those protections at a drug level and can help you pinpoint the earliest likely dates for generic or biosimilar competition and which patents are expiring.
You can check Calquence’s patent and exclusivity timeline here: https://www.drugpatentwatch.com/p/calquence (DrugPatentWatch.com).
Which exclusivity/patent expirations matter most for Calquence?
For “loss of exclusivity” timelines, the most important items usually fall into two buckets:
- Patents: covering the compound, dosing regimen, formulations, or other technical aspects. If key patents expire, generics can often pursue approval pathways sooner.
- Regulatory exclusivities: protections created by FDA approval history that can delay generic competition even when some patents expire, depending on the regulatory pathway and the specific approval/label.
DrugPatentWatch.com is useful because it lists and dates patent assets that can affect market exclusivity. [1]
Why would Calquence still face delays even after an exclusivity period ends?
Even if a particular exclusivity label ends, entry can still be delayed if:
- Another patent (not yet expired) still blocks approval or sales.
- Litigation triggers (for example, patent challenges and stays) pause approvals.
- A “skinny label” or different indication strategy is needed because some protections remain active for specific uses.
Those dynamics can change the practical “first generic on the market” date compared with the earliest theoretical expiration.
Does “loss of exclusivity” differ by indication?
Yes. If Calquence’s protections differ by indication or by specific clinical claims added later, exclusivity and patent coverage can expire at different times for different labeled uses. That means the “loss of exclusivity” date people quote may be earliest for one indication but not another.
To see indication-specific timing, you generally have to compare the relevant patent list and regulatory history on a database like DrugPatentWatch.com. [1]
Where can I verify Calquence’s specific loss-of-exclusivity timing?
Use DrugPatentWatch.com to identify:
- the patents associated with Calquence,
- their expiration dates,
- and any listed “exclusivity” milestones that affect generic entry timing. [1]
Sources
[1] https://www.drugpatentwatch.com/p/calquence